KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia
Cancer · 2025-07 · 131 (13)
DOI: 10.1002/cncr.35941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 18.06.2025. Verfasst von Yibo Wu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloid-Lymphoid Leukemia Protein, Mutation, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
KMT2A (11q23)‐rearranged acute myeloid leukemia ( KMT2A ‐r AML) represents a clinically aggressive subtype with heterogeneous outcomes. Current evidence remains inconclusive regarding the prognostic relevance of fusion partners in 11q23/ KMT2A ‐rearranged AML. The comprehensive mutational landscape and prognostic implications of co‐occurring driver mutations remain poorly characterized.
Methods
A comprehensive clinicogenomic analysis of 159 de novo KMT2A ‐r AML patients was conducted to assess the correlation between molecular profiles and clinical outcomes.
Results
Notably, the KMT2A::MLLT4 subgroup exhibited significantly higher KRAS mutation frequencies compared to other rearrangement groups ( p < .05). Survival analysis revealed that the KMT2A::MLLT4 cohort demonstrated trends toward inferior overall survival (OS) and increased cumulative incidence of relapse (CIR) relative to other rearrangement subgroups. Stratified by mutational status, patients with KRAS mutations exhibited significantly inferior 2‐year OS rates (24.6% vs. 50.5%; p = .001) and higher 2‐year CIR (56.3% vs. 34.6%; p = .018) compared to KRAS wild‐type counterparts. This adverse prognostic association remained in the transplanted cohort (OS: 32.3% vs. 73.5%; p < .001; CIR: 73.6% vs. 23.0%; p < .001). In contrast, mutations in NRAS , FLT3 did not demonstrate statistically significant associations with OS or CIR in either the overall cohort or transplant subgroup. Multivariable Cox regression confirmed KRAS mutation as an independent adverse prognostic factor for both 2‐year OS (hazard ratio [HR], 0.51; 95% CI, 0.31–0.84; p = .008) and CIR (HR, 1.80; 95% CI, 1.04–3.12; p = .037) in the overall cohort. This association persisted in the transplanted patients subgroup (OS: HR, 0.18; 95% CI, 0.06–0.52; p = .001; CIR: HR, 3.89; 95% CI, 1.05–14.37; p = .042).
Conclusions
These results demonstrate the independent prognostic value of KRAS mutations across treatment modalities, including both conventional chemotherapy and hematopoietic stem cell transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center of the First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China.
- Department of Hematology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, Y., Yuan, X., Lai, X., Liu, L., Liang, Y., Yang, L., Zhu, P., Shi, J., Yu, J., Zhao, Y., Zheng, W., Sun, J., Zhu, Y., Wu, W., Cai, Z., Huang, H., Pei, S., & Luo, Y. (2025). KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia. Cancer, 131(13). https://doi.org/10.1002/cncr.35941
Vancouver
Wu Y, Yuan X, Lai X, Liu L, Liang Y, Yang L, et al. KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia. Cancer. 2025;131(13). doi:10.1002/cncr.35941
BibTeX
@article{Wu2025,
author = {Wu, Yibo and Yuan, Xiaolin and Lai, Xiaoyu and Liu, Lizhen and Liang, Yue and Yang, Luxin and Zhu, Panpan and Shi, Jimin and Yu, Jian and Zhao, Yanmin and Zheng, Weiyan and Sun, Jie and Zhu, Yuanyuan and Wu, Wenjun and Cai, Zhen and Huang, He and Pei, Shanshan and Luo, Yi},
title = {KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia},
journal = {Cancer},
year = {2025},
volume = {131},
number = {13},
doi = {10.1002/cncr.35941}
}
EUVIMED